标靶药物递送系统市场：依药物类型、给药途径、技术、治疗应用、最终用户和销售管道划分－2026年至2032年全球市场预测

预计到 2025 年，标靶药物输送系统市场价值将达到 130.4 亿美元，到 2026 年将成长至 139.2 亿美元，到 2032 年将达到 213.2 亿美元，复合年增长率为 7.26%。

主要市场统计数据
基准年 2025	130.4亿美元
预计年份：2026年	139.2亿美元
预测年份 2032	213.2亿美元
复合年增长率 (%)	7.26%

这是一本关于标靶药物递送的权威指南，概述了临床重点、转化研究挑战以及对开发人员和相关人员的战略意义。

标靶药物递送技术透过实现精准定位、可控释放和提高治疗指数，正在变革临床实践、产品开发和患者疗效。本文概述了递送方式创新、先进载体整合以及生物製药与新型化学品融合的战略重要性，为理解临床应用和商业性化优先排序背后的驱动因素奠定了基础。

载体的科学突破、与生物製药的整合以及不断变化的监管和支付方期望如何从根本上重塑标靶递送的发展。

标靶药物递送领域正经历着一场变革，其驱动力包括深刻的生物学见解、平台工程的突破以及监管机构对安全性和真实世界数据的日益重视。载体设计的进步，包括精确的奈米颗粒表面化学和配体驱动的靶向，正在提高治疗指数，并为以往难以成药的靶点开闢新的可能性。同时，递送技术与基因和细胞疗法的融合正在催生混合疗法，拓展治疗应用范围，这也对新的生产和品管系统提出了更高的要求。

对近期美国关税变化如何影响开发商的供应链多元化、区域製造地决策和采购弹性进行实际分析。

美国近期关税政策的变化为定向输送系统开发商和製造商在供应链规划、零件采购和成本结构方面带来了新的考量。依赖国际采购的特殊添加剂、先进聚合物或精密製造设备的製造商正面临日益复杂的采购流程。这些变化促使各企业重新评估其供应商多元化策略，考虑区域化生产，并评估关键上游工程投入品的垂直整合，以降低贸易政策波动带来的风险。

透过提供基于细分的详细观点，将治疗领域、给药途径、平台技术、药物模式、终端用户环境和销售管道联繫起来，我们确定了发展中的关键转折点。

要深入了解市场细分，需要整合治疗领域、给药途径、技术平台、药物模式、终端用户趋势和销售管道，从而形成对市场采纳驱动因素的多维度观点。基于治疗应用，该领域涵盖自体免疫疾病、心血管疾病、中枢神经系统疾病、肿瘤和整形外科适应症，其中肿瘤研究进一步细分为乳癌、结直肠癌和肺癌，每种癌症都需要独特的靶向策略和安全性特征。给药途径细分包括吸入、眼内、静脉注射、局部注射、口服和经皮给药，其中吸入途径本身又可进一步分为干粉吸入器、定量吸入器和雾化器，这些因素决定了製剂和装置的要求。

美洲、欧洲、中东和非洲以及亚太地区的趋势将如何对药物给药技术的监管方法、生产策略和临床应用产生不同的影响？

区域趋势影响技术采纳、监管策略和供应链结构，导致各区域临床重点、报销模式和生产生态系统各不相同。在美洲，强大的临床试验网络、完善的报销框架和以规模化为导向的生产能力，为快速转化研究和商业化策略提供了支持，这些策略优先考虑卫生经济学证据。在该地区运作的申办者通常优先考虑与复杂的医疗服务提供者係统互通性，以及顺利纳入处方集和临床指南的流程。

透过平台扩充性、品质系统和主导商业化，企业采取策略行动和合作模式，在目标交付领域创造竞争优势。

精准医疗领域的主要企业正透过平台扩充性、合规性和为支付方和医疗服务提供者创造综合价值等关键领域实现差异化竞争。与技术开发人员和大型製造商建立策略合作伙伴关係，加速了商业化进程；而与临床网路的伙伴关係有助于设计以真实世界疗效为导向的可操作性临床试验。投资于模组化製造技术和完善品质系统的公司，透过缩短技术转移週期和简化监管检查流程，正在建立竞争优势。

为减少转化障碍、保障供应链、透过主导开发和策略伙伴关係加速临床部署，提出综合可行的建议。

产业领导者应优先采取一系列切实可行的措施，以减少转化阻力、确保供应连续性并加速临床应用。首先，透过将以疗效为导向的终点指标纳入早期临床通讯协定，并使这些终点指标与支付方的证据预期保持一致，从而简化报销谈判。其次，透过关键材料来源多元化以及评估近岸外包和双重采购方案，降低贸易政策和物流中断带来的风险。第三，投资于模组化、符合GMP规范的生产技术，以支援快速规模化生产并简化跨区域技术转移。

我们透明严谨的调查方法，结合了对专家的直接访谈、对第二手资料的全面整合以及交叉检验，从而得出可靠且可操作的见解。

本研究途径整合了定性和定量方法，建构了一个经过验证且三角验证的证据基础，以检验。主要研究包括对製药科学家、临床研究人员、监管专家、生产经理和采购负责人进行结构化访谈，以获取关于技术性能、应用障碍和营运限制的第一手观点。次要研究整合了同行评审文献、监管指导文件、临床试验註册信息和企业资讯披露信息，以阐明技术趋势和监管预期。

简明扼要地整合了策略挑战，展示了综合开发、有韧性的供应链和证据一致性如何决定跨治疗领域的转化研究的成功。

综上所述，这些研究结果表明，标靶药物递送技术正处于一个转折点，科学创新、监管进步和切实可行的商业化策略在此交汇融合，释放出在多种适应症领域的巨大治疗潜力。成功不仅取决于技术优势，还取决于建立循证框架、确保稳健的供应链以及使产品特性与临床工作流程相匹配的能力。那些采用整合式开发计划、投资建设高度灵活的生产设施并及早与监管机构和支付方等相关人员进行沟通的企业，将能够开闢一条永续的推广之路。

目录

第一章：序言

第二章：调查方法

• 调查设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查的前提
• 研究限制

第三章执行摘要

• 首席体验长观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会映射
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按药物类型分類的标靶药物递送系统市场

• 生物製药
• 核酸
• 胜肽
• 低分子化合物

第九章 依给药途径分類的标靶药物递送系统市场

• 吸入
  • 干粉吸入器
  • 定量吸入器
  • 喷雾器
• 眼
• 静脉
• 局部注射
• 口服
• 经皮

第十章 标靶药物递送系统市场：依技术划分

• 抗体药物复合体
• 树状聚合物
• 脂质体
• 微球
• 奈米颗粒

第十一章 按治疗应用分類的标靶药物递送系统市场

• 自体免疫
• 心血管系统
• 中枢神经系统
• 肿瘤学
  • 乳癌
  • 结肠癌
  • 肺癌
• 整形外科

第十二章 标靶药物递送系统市场：依最终用户划分

• 门诊手术中心
• 诊所
• 医院
• 研究机构

第十三章 标靶药物递送系统市场：依销售管道划分

• 直接竞标
• 医院药房
• 网路药房
• 零售药房

第十四章 标靶药物递送系统市场：按地区划分

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章 标靶药物递送系统市场：依组别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章 标靶药物递送系统市场：依国家划分

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章：美国标靶药物传输系统市场

第十八章：中国标靶药物递送系统市场

第十九章 竞争情势

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• AbbVie Inc.
• AstraZeneca PLC
• F. Hoffmann-La Roche Ltd
• GSK plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.

The Targeted Drug Delivery System Market was valued at USD 13.04 billion in 2025 and is projected to grow to USD 13.92 billion in 2026, with a CAGR of 7.26%, reaching USD 21.32 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 13.04 billion
Estimated Year [2026]	USD 13.92 billion
Forecast Year [2032]	USD 21.32 billion
CAGR (%)	7.26%

An authoritative orientation to targeted drug delivery that frames clinical priorities, translational hurdles, and strategic implications for developers and healthcare stakeholders

Targeted drug delivery technologies are reshaping clinical practice, product development, and patient outcomes by enabling precise localization, controlled release, and improved therapeutic indices. This introduction frames the strategic importance of delivery modality innovation, integration of advanced carriers, and the intersection of biologics and novel chemistries, setting a foundation for understanding the drivers behind clinical adoption and commercial prioritization.

Clinical stakeholders increasingly prioritize delivery approaches that reduce systemic exposure, minimize dosing frequency, and enhance patient adherence, while developers focus on platform scalability and regulatory tractability. Against this backdrop, the report synthesizes technological advances, regulatory dynamics, and translational barriers, creating a coherent narrative that informs research investment decisions and portfolio alignment for organizations navigating the evolving targeted delivery landscape.

How scientific breakthroughs in carriers, convergence with biotherapeutics, and evolving regulatory and payer expectations are fundamentally reconfiguring targeted delivery development

The targeted drug delivery landscape is undergoing transformative shifts driven by deeper biological insights, platform engineering breakthroughs, and evolving regulatory emphasis on safety and real-world evidence. Advances in carrier design, including precision nanoparticle surface chemistry and ligand-directed targeting, are enabling higher therapeutic indices and opening new windows for previously undruggable targets. Concurrently, the convergence of delivery technologies with gene and cell modalities is creating hybrid approaches that expand therapeutic reach and demand novel manufacturing and quality frameworks.

Parallel shifts in payer and provider expectations emphasize value demonstrated through improved outcomes and healthcare utilization metrics, prompting developers to build more robust evidence packages and to pursue pragmatic clinical endpoints. The rapid iteration of inhalation, ocular, and localized injection strategies for site-specific therapies reflects an industry eager to balance efficacy gains with patient-centric delivery. Taken together, these forces are accelerating translational pathways while elevating the importance of cross-disciplinary partnerships between formulation scientists, clinicians, and regulatory specialists.

Practical analysis of how recent United States tariff changes compel supply chain diversification, regional manufacturing decisions, and procurement resilience for developers

Recent tariff developments in the United States have injected new considerations into supply chain planning, component sourcing, and cost structures for developers and manufacturers of targeted delivery systems. Manufacturers that rely on specialized excipients, advanced polymers, or precision manufacturing equipment sourced internationally face increased procurement complexity. These dynamics are prompting organizations to reassess supplier diversification strategies, consider regionalized manufacturing, and evaluate vertical integration for critical upstream inputs to mitigate exposure to trade policy volatility.

The tariff environment also influences decisions on clinical and commercial manufacturing footprints as sponsors weigh the trade-offs between cost, lead time, and regulatory consistency. For many organizations, the cumulative effect of tariffs has catalyzed a re-evaluation of nearshoring and dual-sourcing models to preserve program timelines and maintain predictable product quality. Companies that proactively adapt contracting practices, incorporate tariff sensitivity into procurement analytics, and engage in collaborative supply chain transparency are better positioned to maintain continuity amid policy shifts.

Deep segmentation-driven perspective that interlinks therapeutic areas, delivery routes, platform technologies, drug modalities, end-user settings, and sales channels to reveal critical development inflection points

Segmentation insight requires integrating therapeutic focus, delivery route, technology platform, drug modality, end-user dynamics, and sales pathways to form a multidimensional view of adoption drivers. Based on therapeutic application, the field encompasses autoimmune, cardiovascular, central nervous system, oncology, and orthopedic indications, with oncology research further differentiated into breast, colorectal, and lung cancers, each demanding distinct targeting strategies and safety profiles. Delivery route segmentation captures inhalation, intraocular, intravenous, local injection, oral, and transdermal approaches, and recognizes that inhalation itself breaks down into dry powder inhaler, metered dose inhaler, and nebulizer formats that shape formulation and device requirements.

Technology segmentation highlights the heterogeneity of platform engineering, spanning antibody drug conjugates, dendrimers, liposomes, microspheres, and nanoparticles, each presenting unique pharmacokinetic and regulatory considerations. Drug type distinctions among biologics, nucleic acids, peptides, and small molecules determine stability, encapsulation needs, and analytical controls, while end users such as ambulatory surgical centers, clinics, hospitals, and research institutes influence deployment logistics and training requirements. Finally, sales channel segmentation that includes direct tender, hospital pharmacy, online pharmacy, and retail pharmacy affects commercialization planning, reimbursement interactions, and post-market surveillance strategies. When these dimensions are cross-referenced, they reveal high-value combinations and critical development inflection points where scientific choices intersect with clinical pathways and commercial access.

How Americas, Europe Middle East & Africa, and Asia-Pacific regional dynamics distinctly influence regulatory approaches, manufacturing strategies, and clinical adoption of delivery technologies

Regional dynamics shape technology adoption, regulatory strategy, and supply chain architecture, with each region presenting distinct clinical priorities, reimbursement models, and manufacturing ecosystems. In the Americas, robust clinical trial networks, established reimbursement frameworks, and scale-oriented manufacturing capacity favor rapid translational efforts and commercialization strategies that emphasize health-economic evidence. Sponsors operating in this region frequently prioritize interoperability with complex provider systems and navigable pathways for inclusion in formularies and clinical guidelines.

Europe, the Middle East & Africa present a heterogeneous regulatory and payer landscape where regional harmonization efforts coexist with country-specific requirements, creating both collaborative opportunities through centralized assessment bodies and localized access challenges. In these territories, value demonstration and real-world data are pivotal to securing adoption across diverse healthcare systems. Asia-Pacific combines rapid demand growth with evolving regulatory sophistication, strong contract manufacturing presence, and a growing emphasis on domestic innovation. Companies targeting this region often balance expedited commercialization with the need to adapt to local clinical preferences and manufacturing partnerships, optimizing product profiles to meet variable delivery route preferences and patient adherence considerations.

Strategic company behaviors and collaborative models that drive competitive advantage through platform scalability, quality systems, and evidence-led commercialization in targeted delivery

Leading companies in the targeted delivery space are differentiating through focus areas that include platform scalability, regulatory alignment, and integrated value generation for payers and providers. Strategic collaborations between technology developers and large-scale manufacturers are accelerating commercial readiness, while partnerships with clinical networks enable the design of pragmatic trials that emphasize real-world outcomes. Firms investing in modular manufacturing technologies and robust quality systems are creating competitive advantages by shortening tech transfer timelines and easing regulatory inspections.

Intellectual property strategies remain central, with forward-looking organizations protecting core formulation approaches and device interfaces while pursuing freedom-to-operate for combination products. Business models vary from platform license plays to fully integrated product development and commercialization, and successful players combine deep translational expertise with disciplined external engagement-policy stakeholders, payers, and patient advocacy groups-to align product value with clinical unmet needs. Companies that pair technical excellence with transparent evidence generation and adaptive commercialization channels are best positioned to translate scientific promise into clinical impact.

Consolidated and pragmatic recommendations for reducing translational barriers, securing supply chains, and accelerating clinical adoption through evidence-driven development and strategic partnerships

Industry leaders should prioritize a set of actionable initiatives that reduce translational friction, protect supply continuity, and accelerate clinical adoption. First, embed delivery-focused endpoints into early clinical protocols and align those endpoints with payer evidence expectations to streamline reimbursement conversations. Second, diversify sourcing for critical materials and evaluate nearshoring or dual-sourcing options to reduce exposure to trade policy and logistics disruptions. Third, invest in modular, GMP-compliant manufacturing technologies that support rapid scale-up and simplify tech transfer across geographies.

Additionally, cultivate interdisciplinary teams that bring formulation scientists, clinicians, health economists, and regulatory experts into continuous collaboration to anticipate approval hurdles and optimize product profiles. Strengthen IP strategies around combination products and device interfaces while exploring strategic licensing to broaden application reach. Finally, pursue targeted partnerships with healthcare providers and patient groups to design adoption-friendly delivery formats and patient support services that improve real-world outcomes and clinician acceptance. These actions create a pragmatic pathway from laboratory innovation to durable clinical implementation.

Transparent and rigorous research methodology combining primary expert interviews, comprehensive secondary synthesis, and cross-validation to support robust and actionable insights

The research approach integrates qualitative and quantitative methods to build a validated, triangulated evidence base for analysis. Primary research included structured interviews with formulation scientists, clinical investigators, regulatory experts, manufacturing leads, and procurement officers to capture firsthand perspectives on technology performance, adoption barriers, and operational constraints. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to contextualize technological trends and regulatory expectations.

Data synthesis applied cross-validation techniques to reconcile disparate information sources, and scenario analysis was used to stress-test supply chain and regulatory contingencies. Where gaps were identified, targeted follow-up interviews and document requests addressed uncertainties and enhanced confidence in the conclusions. The methodology emphasizes transparency about data provenance and acknowledged limitations, advising readers on the interpretive boundaries of the findings and on the importance of complementing this analysis with program-specific due diligence.

Concise synthesis of strategic imperatives showing how integrated development, resilient supply chains, and evidence alignment will determine translational success across therapeutic areas

The aggregate insights highlight that targeted drug delivery is at an inflection point where scientific innovation, regulatory evolution, and pragmatic commercialization strategies converge to unlock therapeutic potential across multiple indications. Success hinges not only on technological superiority but also on the ability to design evidence frameworks, secure resilient supply chains, and align product characteristics with clinical workflows. Organizations that adopt integrated development plans, invest in adaptable manufacturing, and engage early with regulatory and payer stakeholders will create durable pathways to adoption.

Looking forward, stakeholders should expect incremental advances in carrier engineering and device integration to continue expanding the therapeutic boundaries, particularly where delivery enables safer administration of potent therapeutics or targeted modulation of disease biology. The combination of strategic partnerships, disciplined execution, and a relentless focus on real-world impact will determine which innovations translate into measurable improvements in patient care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted Drug Delivery System Market, by Drug Type

• 8.1. Biologics
• 8.2. Nucleic Acids
• 8.3. Peptides
• 8.4. Small Molecule

9. Targeted Drug Delivery System Market, by Delivery Route

• 9.1. Inhalation
  • 9.1.1. Dry Powder Inhaler
  • 9.1.2. Metered Dose Inhaler
  • 9.1.3. Nebulizer
• 9.2. Intraocular
• 9.3. Intravenous
• 9.4. Local Injection
• 9.5. Oral
• 9.6. Transdermal

10. Targeted Drug Delivery System Market, by Technology

• 10.1. Antibody Drug Conjugates
• 10.2. Dendrimers
• 10.3. Liposomes
• 10.4. Microspheres
• 10.5. Nanoparticles

11. Targeted Drug Delivery System Market, by Therapeutic Application

• 11.1. Autoimmune
• 11.2. Cardiovascular
• 11.3. Central Nervous System
• 11.4. Oncology
  • 11.4.1. Breast Cancer
  • 11.4.2. Colorectal Cancer
  • 11.4.3. Lung Cancer
• 11.5. Orthopedic

12. Targeted Drug Delivery System Market, by End User

• 12.1. Ambulatory Surgical Centers
• 12.2. Clinics
• 12.3. Hospitals
• 12.4. Research Institutes

13. Targeted Drug Delivery System Market, by Sales Channel

• 13.1. Direct Tender
• 13.2. Hospital Pharmacy
• 13.3. Online Pharmacy
• 13.4. Retail Pharmacy

14. Targeted Drug Delivery System Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Targeted Drug Delivery System Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Targeted Drug Delivery System Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. United States Targeted Drug Delivery System Market

18. China Targeted Drug Delivery System Market

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025
• 19.5. AbbVie Inc.
• 19.6. AstraZeneca PLC
• 19.7. F. Hoffmann-La Roche Ltd
• 19.8. GSK plc
• 19.9. Johnson & Johnson
• 19.10. Merck & Co., Inc.
• 19.11. Novartis AG
• 19.12. Pfizer Inc.
• 19.13. Sanofi S.A.
• 19.14. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 13. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 14. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NUCLEIC ACIDS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NUCLEIC ACIDS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NUCLEIC ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LOCAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LOCAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LOCAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DENDRIMERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROSPHERES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROSPHERES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 83. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 84. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 85. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 86. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 87. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 88. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 89. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 90. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 91. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 92. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 93. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 94. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 95. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 96. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 97. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 98. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 99. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 100. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 101. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 102. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 103. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 104. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 105. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 106. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 107. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 108. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 109. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 110. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 111. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 112. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 113. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 114. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 115. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 116. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 117. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 118. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 119. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 120. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 121. AMERICAS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 122. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 123. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 124. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 125. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 126. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 127. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 128. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 129. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 130. NORTH AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 131. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 132. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 133. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 134. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 135. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 136. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 137. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 138. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 139. LATIN AMERICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 140. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 141. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 142. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 143. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 144. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 145. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 146. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 147. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 148. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 149. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 150. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 151. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 152. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 153. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 154. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 155. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 156. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 157. EUROPE TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 158. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 159. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 160. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 161. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 162. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 163. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 164. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 165. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 166. MIDDLE EAST TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 167. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 168. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 169. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 170. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 171. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 172. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 173. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 174. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 175. AFRICA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 176. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 177. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 178. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 179. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 180. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 181. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 182. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 183. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 184. ASIA-PACIFIC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 185. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 186. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 187. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 188. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 189. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 190. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 191. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 192. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 193. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 194. ASEAN TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 195. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 196. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 197. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 198. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 199. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 200. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 201. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 202. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 203. GCC TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 204. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 205. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 206. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 207. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 208. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 209. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 210. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 211. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 212. EUROPEAN UNION TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 213. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 214. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 215. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 216. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 217. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 218. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 219. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 220. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 221. BRICS TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 222. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 223. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 224. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 225. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 226. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 227. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 228. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 229. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 230. G7 TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 231. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 232. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 233. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 234. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 235. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 236. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 237. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 238. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 239. NATO TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 240. GLOBAL TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 241. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 242. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 243. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 244. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 245. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 246. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 247. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 248. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 249. UNITED STATES TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
• TABLE 250. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 251. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 252. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY ROUTE, 2018-2032 (USD MILLION)
• TABLE 253. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
• TABLE 254. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 255. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 256. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 257. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 258. CHINA TARGETED DRUG DELIVERY SYSTEM MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)